Show simple item record

dc.contributor.authorBonaccorso, Stefania
dc.contributor.authorMetastasio, Antonio
dc.contributor.authorRicciardi, Angelo
dc.contributor.authorStewart, Neil
dc.contributor.authorJamal, Leila
dc.contributor.authorRujully, Naasir Ud Dinn
dc.contributor.authorTheleritis, Christos
dc.contributor.authorFerracuti, Stefano
dc.contributor.authorDucci, Giuseppe
dc.contributor.authorSchifano, Fabrizio
dc.date.accessioned2018-09-28T09:12:01Z
dc.date.available2018-09-28T09:12:01Z
dc.date.issued2018-07-14
dc.identifier.citationBonaccorso , S , Metastasio , A , Ricciardi , A , Stewart , N , Jamal , L , Rujully , N U D , Theleritis , C , Ferracuti , S , Ducci , G & Schifano , F 2018 , ' Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings : Clinical presentation and management issues ' , Brain Sciences , vol. 8 , no. 7 , 133 . https://doi.org/10.3390/brainsci8070133
dc.identifier.issn2076-3425
dc.identifier.otherPURE: 15402463
dc.identifier.otherPURE UUID: 0d8637a7-e660-4d3c-969d-97538d8e3f47
dc.identifier.otherScopus: 85050809264
dc.identifier.urihttp://hdl.handle.net/2299/20656
dc.description.abstractBackground: Novel Psychoactive Substances (NPS) are a heterogeneous class of synthetic molecules including synthetic cannabinoid receptor agonists (SCRAs). Psychosis is associated with SCRAs use. There is limited knowledge regarding the structured assessment and psychometric evaluation of clinical presentations, analytical toxicology and clinical management plans of patients presenting with psychosis and SCRAs misuse. Methods: We gathered information regarding the clinical presentations, toxicology and care plans of patients with psychosis and SCRAs misuse admitted to inpatients services. Clinical presentations were assessed using the PANSS scale. Vital signs data were collected using the National Early Warning Signs tool. Analytic chemistry data were collected using urine drug screening tests for traditional psychoactive substances and NPS. Results: We described the clinical presentation and management plan of four patients with psychosis and misuse of SCRAs. Conclusion: The formulation of an informed clinical management plan requires a structured assessment, identification of the index NPS, pharmacological interventions, increases in nursing observations, changes to leave status and monitoring of the vital signs. The objective from using these interventions is to maintain stable physical health whilst rapidly improving the altered mental state.en
dc.format.extent10
dc.language.isoeng
dc.relation.ispartofBrain Sciences
dc.rightsOpen
dc.subjectAntipsychotics
dc.subjectMental health
dc.subjectNovel psychoactive substances
dc.subjectNPs
dc.subjectNPs testing
dc.subjectNursing care
dc.subjectPhysical health
dc.subjectPsychosis
dc.subjectSCRAs
dc.subjectSynthetic cannabinoids
dc.subjectNeuroscience(all)
dc.titleSynthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings : Clinical presentation and management issuesen
dc.contributor.institutionUniversity of Hertfordshire
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85050809264&partnerID=8YFLogxK
dc.description.versiontypeFinal Published version
dcterms.dateAccepted2018-07-14
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.3390/brainsci8070133
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue
herts.rights.accesstypeOpen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record